132 related articles for article (PubMed ID: 15869448)
1. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2.
Quan WD; Khan N; Ramirez M; Taylor WC; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Apr; 20(2):151-4. PubMed ID: 15869448
[TBL] [Abstract][Full Text] [Related]
2. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Quan WD; Walker PR; Quan FM; Ramirez M; Elsamaloty HM; Ghai V; Vinogradov M; Liles DK
Cancer Biother Radiopharm; 2006 Oct; 21(5):437-42. PubMed ID: 17105418
[TBL] [Abstract][Full Text] [Related]
3. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Quan W; Ramirez M; Taylor C; Quan F; Vinogradov M; Walker P
Cancer Biother Radiopharm; 2005 Feb; 20(1):11-5. PubMed ID: 15778574
[TBL] [Abstract][Full Text] [Related]
4. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
5. High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
Quan W; Ramirez M; Taylor C; Vinogradov M; Quan F; Khan N
Cancer Biother Radiopharm; 2005 Feb; 20(1):36-40. PubMed ID: 15778577
[TBL] [Abstract][Full Text] [Related]
6. [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma].
Nakano E
Hinyokika Kiyo; 1992 Nov; 38(11):1305-9. PubMed ID: 1485586
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Quan WD; Milligan KS; Quan FM; Cuenca RE; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Dec; 21(6):607-12. PubMed ID: 17257076
[TBL] [Abstract][Full Text] [Related]
10. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Ettinghausen SE; Matory YL; Skibber JM; Shiloni E; Vetto JT
N Engl J Med; 1985 Dec; 313(23):1485-92. PubMed ID: 3903508
[TBL] [Abstract][Full Text] [Related]
11. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
Quan WD; Vinogradov M; Quan FM; Khan N; Liles DK; Walker PR
Cancer Biother Radiopharm; 2006 Oct; 21(5):515-9. PubMed ID: 17105423
[TBL] [Abstract][Full Text] [Related]
13. Bolus high dose interleukin-2 for the treatment of malignant melanoma.
Pappo I; Lotem M; Klein M; Orda R
Isr Med Assoc J; 2001 Mar; 3(3):169-73. PubMed ID: 11303372
[TBL] [Abstract][Full Text] [Related]
14. Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2003 Aug; 18(4):535-8. PubMed ID: 14503947
[TBL] [Abstract][Full Text] [Related]
15. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
[TBL] [Abstract][Full Text] [Related]
16. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Quan WD; Quan FM
Cancer Biother Radiopharm; 2009 Feb; 24(1):1-6. PubMed ID: 19243244
[TBL] [Abstract][Full Text] [Related]
17. High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Quan W; Ramirez M; Taylor WC; Vinogradov M; Khan N; Jackson S
Cancer Biother Radiopharm; 2004 Dec; 19(6):770-5. PubMed ID: 15665626
[TBL] [Abstract][Full Text] [Related]
18. Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Quan WD; Gagnon GA; Walker PR; Quan FM
Cancer Biother Radiopharm; 2011 Feb; 26(1):65-7. PubMed ID: 21348776
[TBL] [Abstract][Full Text] [Related]
19. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
20. Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.
Vogelzang PJ; Bloom SM; Mier JW; Atkins MB
Chest; 1992 Mar; 101(3):746-52. PubMed ID: 1541142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]